enGene Q1 net loss attributable to common shareholders rises 21% to USD 29.75 million on 17% higher operating expenses of USD 31.19 million

Reuters03-09

enGene Q1 net loss attributable to common shareholders rises 21% to USD 29.75 million on 17% higher operating expenses of USD 31.19 million

enGene reported a Q1 net loss attributable to common shareholders of USD 29.75 million, or USD 0.44 per share. Total operating expenses rose 17% to USD 31.19 million, including R&D expenses up 11% to USD 22.26 million. General and administrative expenses increased 35% to USD 8.93 million. Cash, cash equivalents and marketable securities totaled USD 312.55 million as of Jan. 31, and enGene said it expects this to fund operations into the second half of 2028. Management said a LEGEND pivotal cohort update is planned for a spring 2026 medical conference, with a BLA submission for detalimogene planned for the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603090700BIZWIRE_USPR_____20260309_BW831252) on March 09, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618640489?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618640489","market":"fut","top_or_hot":-1,"title":"enGene Q1 net loss attributable to common shareholders rises 21% to USD 29.75 million on 17% higher operating expenses of USD 31.19 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      enGene Q1 net loss attributable to common shareholders rises 21% to USD 29.75 million on 17% higher operating expenses of USD 31.19 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        enGene reported a Q1 net loss attributable to common shareholders of USD 29.75 million, or USD 0.44 per share. Total operating expenses rose 17% to USD 31.19 million, including R&amp;D expenses up 11% to USD 22.26 million. General and administrative expenses increased 35% to USD 8.93 million. Cash, cash equivalents and marketable securities totaled USD 312.55 million as of Jan. 31, and enGene said it expects this to fund operations into the second half of 2028. Management said a LEGEND pivotal cohort update is planned for a spring 2026 medical conference, with a BLA submission for detalimogene planned for the second half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603090700BIZWIRE_USPR_____20260309_BW831252) on March 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>enGene Q1 net loss attributable to common shareholders rises 21% to USD 29.75 million on 17% higher operating expenses of USD 31.19 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nenGene Q1 net loss attributable to common shareholders rises 21% to USD 29.75 million on 17% higher operating expenses of USD 31.19 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-09 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      enGene Q1 net loss attributable to common shareholders rises 21% to USD 29.75 million on 17% higher operating expenses of USD 31.19 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        enGene reported a Q1 net loss attributable to common shareholders of USD 29.75 million, or USD 0.44 per share. Total operating expenses rose 17% to USD 31.19 million, including R&amp;D expenses up 11% to USD 22.26 million. General and administrative expenses increased 35% to USD 8.93 million. Cash, cash equivalents and marketable securities totaled USD 312.55 million as of Jan. 31, and enGene said it expects this to fund operations into the second half of 2028. Management said a LEGEND pivotal cohort update is planned for a spring 2026 medical conference, with a BLA submission for detalimogene planned for the second half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603090700BIZWIRE_USPR_____20260309_BW831252) on March 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL8M6MDf:1","article_id":"2618640489","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618640489","pubTimestamp":1773054064,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"enGene Q1 net loss attributable to common shareholders rises 21% to USD 29.75 million on 17% higher operating expenses of USD 31.19 million. enGene reported a Q1 net loss attributable to common shareholders of USD 29.75 million, or USD 0.44 per share. Total operating expenses rose 17% to USD 31.19 million, including R&D expenses up 11% to USD 22.26 million. General and administrative expenses increased 35% to USD 8.93 million. Cash, cash equivalents and marketable securities totaled USD 312.55 million as of Jan. 31, and enGene said it expects this to fund operations into the second half of 2028. Management said a LEGEND pivotal cohort update is planned for a spring 2026 medical conference, with a BLA submission for detalimogene planned for the second half of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ENGN":"ENGENE HOLDINGS INC"},"translate_title":"enGene第一季度归属于普通股股东的净亏损增长21%，达到2,975万美元，运营费用增长17%，达到3,119万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENGN":0.9},"content_text":"enGene Q1 net loss attributable to common shareholders rises 21% to USD 29.75 million on 17% higher operating expenses of USD 31.19 million\n    \n\n        enGene reported a Q1 net loss attributable to common shareholders of USD 29.75 million, or USD 0.44 per share. Total operating expenses rose 17% to USD 31.19 million, including R&D expenses up 11% to USD 22.26 million. General and administrative expenses increased 35% to USD 8.93 million. Cash, cash equivalents and marketable securities totaled USD 312.55 million as of Jan. 31, and enGene said it expects this to fund operations into the second half of 2028. Management said a LEGEND pivotal cohort update is planned for a spring 2026 medical conference, with a BLA submission for detalimogene planned for the second half of 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603090700BIZWIRE_USPR_____20260309_BW831252) on March 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618640489","isCrawlerRequest":true}